David F L Liew
Overview
Explore the profile of David F L Liew including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
41
Citations
400
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Leung J, Deeble N, Yang V, Liew D, Buchanan R, Owen C
J Clin Rheumatol
. 2025 Mar;
PMID: 40036143
Objective: To assess the prevalence of and risk factors for depression in a cohort of patients with polymyalgia rheumatica (PMR) compared with a cohort of participants without PMR (control group)....
2.
Sendaydiego X, Gold L, Dubreuil M, Andrews J, Reid P, Liew D, et al.
Rheumatology (Oxford)
. 2025 Feb;
PMID: 39936579
Objectives: To assess the comparative safety of tumor necrosis factor inhibitor (TNFi), non-TNFi, and Janus kinase inhibitor (JAKi) biologic or targeted synthetic disease-modifying anti-rheumatic drugs (b/tsDMARD) in patients with rheumatoid...
3.
Sendaydiego X, Gold L, Dubreuil M, Andrews J, Reid P, Liew D, et al.
JAMA Netw Open
. 2024 Nov;
7(11):e2446336.
PMID: 39565623
Importance: The Oral Rheumatoid Arthritis Trial Surveillance demonstrated an increased cancer risk among patients with rheumatoid arthritis (RA) taking tofacitinib compared with those taking tumor necrosis factor inhibitors (TNFis). Although...
4.
Ghang B, Park J, Lee J, Lim J, Kim H, Liew D, et al.
Kidney Int
. 2024 Nov;
107(3):521-529.
PMID: 39551133
Based on the hypothesis that hyperuricemia is a modifiable risk factor for chronic kidney disease (CKD) progression, there is an expectation that urate-lowering therapy (ULT) could delay the progression of...
5.
Hill C, Pulver L, Liew D
Intern Med J
. 2024 Sep;
54(10):1733-1738.
PMID: 39329217
High-cost medicines (HCMs) can be clinically impactful for individual patients but are also subject to variable funding mechanisms. Public hospitals and health services are often asked to fund HCMs, but...
6.
Owen C, Liew D, Liew D
Rheumatology (Oxford)
. 2024 Jul;
63(12):3208-3210.
PMID: 39024054
No abstract available.
7.
Skaarup L, Ingrid E, Sepriano A, Nikiphorou E, Ostgard R, Lauper K, et al.
Drug Saf
. 2024 Jul;
47(11):1075-1093.
PMID: 39012469
Background/aim: The purpose of this review is to provide an overview of the contraindications, special warnings, and boxed warnings with the aim to establish a framework to create a prescription...
8.
Eades L, Hoi A, Liddle R, Sines J, Kandane-Rathnayake R, Khetan S, et al.
Lancet Rheumatol
. 2024 Jul;
6(10):e713-e726.
PMID: 38971169
The first inhabitants of Australia and the traditional owners of Australian lands are the Aboriginal and Torres Strait Islander peoples. Aboriginal and Torres Strait Islander peoples are two to four...
9.
Rheumatic Immune-Related Adverse Events: Current Clinical Imperatives Underpin Future Novel Insights
Liew D, Simon Meara A
Rheum Dis Clin North Am
. 2024 Apr;
50(2):xvii-xix.
PMID: 38670733
No abstract available.
10.
Ghosh N, Jivanelli B, Couette N, Singh N, Kostine M, Simon Meara A, et al.
Rheum Dis Clin North Am
. 2024 Apr;
50(2):325-335.
PMID: 38670730
Immune checkpoint inhibitor-induced inflammatory arthritis (ICI-IA) is an immune-related adverse event that can occur as a result of receiving ICIs for cancer treatment. Thus far, ICI-IA has been described variably...